Clinical research
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 5, 2021.
Calithera Biosciences reported that its CANTATA clinical trial of telaglenastat in patients with advanced or metastatic renal cell carcinoma (RCC) failed to hit the primary endpoint.
It’s not particularly surprising that there wasn’t a lot of clinical trial news between Christmas and New Year’s, although there was some. Here’s a look.
Axsome Therapeutics reported positive data from the long-term, open-label Phase III MOVEMENT trial of AXS-07 for the treatment of acute migraine.
Sinopharm, a Chinese biopharmaceutical company controlled by the state, announced that its COVID-19 vaccine candidate had an efficacy rate of 79% based on interim analysis of Phase III trials.
Fabry disease is a rare, X-linked inherited disease that results from abnormal deposits of a fatty substance in blood vessels.
Shares of Aprea Therapeutics plunged more than 77% in morning trading after the company announced its late-stage cancer combination treatment failed to meet its primary endpoint of complete remission rate.
Even with the holidays among us, there were a number of clinical trial announcements. Here’s a look.
In October, the FDA placed a clinical hold on the company’s Huntington’s disease gene therapy before that asset could make its way into the clinic.
As a result, the company has decided to unblind the treatment assignments of patients in the trial.
PRESS RELEASES